HIV capsid inhibition: Difference between revisions

Add links
From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
→‎Therapeutic applications: claims removed, also outdated, added "research"
Line 1: Line 1:
In the [[management of HIV/AIDS]], '''HIV capsid inhibitors''' are antiretroviral medicines that target the [[capsid]] shell of the virus. Most current antiretroviral drugs used to treat HIV do not directly target the viral capsid.<ref name=":0">{{cite journal | vauthors = Thenin-Houssier S, de Vera IM, Pedro-Rosa L, Brady A, Richard A, Konnick B, Opp S, Buffone C, Fuhrmann J, Kota S, Billack B, Pietka-Ottlik M, Tellinghuisen T, Choe H, Spicer T, Scampavia L, Diaz-Griffero F, Kojetin DJ, Valente ST | display-authors = 6 | title = Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication | journal = Antimicrobial Agents and Chemotherapy | volume = 60 | issue = 4 | pages = 2195–2208 | date = April 2016 | pmid = 26810656 | pmc = 4808204 | doi = 10.1128/AAC.02574-15 }}</ref> Because of this, drugs that specifically inhibit the HIV capsid are being developed in order to reduce the replication of HIV, and treat infections that have become resistant to current antiretroviral therapies.
In the [[management of HIV/AIDS]], '''HIV capsid inhibitors''' are antiretroviral medicines that target the [[capsid]] shell of the virus. Most current antiretroviral drugs used to treat HIV do not directly target the viral capsid.<ref>{{Cite web |title=FDA-Approved HIV Medicines {{!}} NIH |url=https://hivinfo.nih.gov/understanding-hiv/fact-sheets/fda-approved-hiv-medicines |access-date=2023-05-25 |website=hivinfo.nih.gov |language=en}}</ref> These have also been termed "Capsid-targeting Antivirals", "Capsid Effectors", and "Capsid Assembly Modulators (CAMs)". Because of this, drugs that specifically inhibit the HIV capsid are being developed in order to reduce the replication of HIV, and treat infections that have become resistant to current antiretroviral therapies.<ref name=":3">{{Cite journal |last=McFadden |first=William M. |last2=Snyder |first2=Alexa A. |last3=Kirby |first3=Karen A. |last4=Tedbury |first4=Philip R. |last5=Raj |first5=Monika |last6=Wang |first6=Zhengqiang |last7=Sarafianos |first7=Stefan G. |date=2021-12-22 |title=Rotten to the core: antivirals targeting the HIV-1 capsid core |url=https://doi.org/10.1186/s12977-021-00583-z |journal=Retrovirology |volume=18 |issue=1 |pages=41 |doi=10.1186/s12977-021-00583-z |issn=1742-4690 |pmc=PMC8693499 |pmid=34937567}}</ref>


== History and background ==
== History and background ==
Line 12: Line 12:


=== HIV treatment ===
=== HIV treatment ===
Current drugs administered in the treatment of HIV do not target the capsid. Instead, patients are given a cocktail of [[Reverse-transcriptase inhibitor|reverse transcriptase inhibitors]], [[Protease inhibitor (pharmacology)|protease inhibitors]], [[integrase inhibitor]]s, and [[entry inhibitor]]s.<ref name=":0" /> These drugs have been successful on an epidemiologic and individual basis. With treatment, people infected by HIV are able to live long and healthy lives.<ref name=":1">{{cite journal | vauthors = Moreno S, López Aldeguer J, Arribas JR, Domingo P, Iribarren JA, Ribera E, Rivero A, Pulido F | display-authors = 6 | title = The future of antiretroviral therapy: challenges and needs | journal = The Journal of Antimicrobial Chemotherapy | volume = 65 | issue = 5 | pages = 827–835 | date = May 2010 | pmid = 20228080 | doi = 10.1093/jac/dkq061 | doi-access = free }}</ref>
Current drugs administered in the treatment of HIV do not target the capsid. Instead, patients are given a cocktail of [[Reverse-transcriptase inhibitor|reverse transcriptase inhibitors]], [[Protease inhibitor (pharmacology)|protease inhibitors]], [[integrase inhibitor]]s, and [[entry inhibitor]]s.<ref name=":0">{{cite journal |display-authors=6 |vauthors=Thenin-Houssier S, de Vera IM, Pedro-Rosa L, Brady A, Richard A, Konnick B, Opp S, Buffone C, Fuhrmann J, Kota S, Billack B, Pietka-Ottlik M, Tellinghuisen T, Choe H, Spicer T, Scampavia L, Diaz-Griffero F, Kojetin DJ, Valente ST |date=April 2016 |title=Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication |journal=Antimicrobial Agents and Chemotherapy |volume=60 |issue=4 |pages=2195–2208 |doi=10.1128/AAC.02574-15 |pmc=4808204 |pmid=26810656}}</ref> These drugs have been successful on an epidemiologic and individual basis. With treatment, people infected by HIV are able to live long and healthy lives.<ref name=":1">{{cite journal | vauthors = Moreno S, López Aldeguer J, Arribas JR, Domingo P, Iribarren JA, Ribera E, Rivero A, Pulido F | display-authors = 6 | title = The future of antiretroviral therapy: challenges and needs | journal = The Journal of Antimicrobial Chemotherapy | volume = 65 | issue = 5 | pages = 827–835 | date = May 2010 | pmid = 20228080 | doi = 10.1093/jac/dkq061 | doi-access = free }}</ref>


As current treatments significantly reduce the mortality and morbidity of HIV, the disease is incurable but chronically manageable. Because patients typically need to take antiretroviral medications for the rest of their lives, long-term effects of [[Management of HIV/AIDS|HIV treatment]] are important to consider. Long term toxicological effects of antiretroviral treatments can sometimes cause secondary morbidities even when the viral count is low.<ref name=":1" /> Additionally, drug resistances can be acquired or transmitted due to suboptimal pharmokinetics or lack of patient adherence to treatment.<ref>{{cite journal | vauthors = Taiwo B, Hicks C, Eron J | title = Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1 | journal = The Journal of Antimicrobial Chemotherapy | volume = 65 | issue = 6 | pages = 1100–1107 | date = June 2010 | pmid = 20348088 | doi = 10.1093/jac/dkq096 | doi-access = free }}</ref>
As current treatments significantly reduce the mortality and morbidity of HIV, the disease is incurable but chronically manageable. Because patients typically need to take antiretroviral medications for the rest of their lives, long-term effects of [[Management of HIV/AIDS|HIV treatment]] are important to consider. Long term toxicological effects of antiretroviral treatments can sometimes cause secondary morbidities even when the viral count is low.<ref name=":1" /> Additionally, drug resistances can be acquired or transmitted due to suboptimal pharmokinetics or lack of patient adherence to treatment.<ref>{{cite journal | vauthors = Taiwo B, Hicks C, Eron J | title = Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1 | journal = The Journal of Antimicrobial Chemotherapy | volume = 65 | issue = 6 | pages = 1100–1107 | date = June 2010 | pmid = 20348088 | doi = 10.1093/jac/dkq096 | doi-access = free }}</ref>
Line 25: Line 25:


== Research ==
== Research ==

=== History ===
In 2003, the first compound to bind the HIV-1 capsid was in reported and termed "CAP-1".<ref>{{Cite journal |last=Tang |first=Chun |last2=Loeliger |first2=Erin |last3=Kinde |first3=Isaac |last4=Kyere |first4=Samson |last5=Mayo |first5=Keith |last6=Barklis |first6=Eric |last7=Sun |first7=Yongnian |last8=Huang |first8=Mingjun |last9=Summers |first9=Michael F |date=2003-04-11 |title=Antiviral Inhibition of the HIV-1 Capsid Protein |url=https://www.sciencedirect.com/science/article/pii/S0022283603002894 |journal=Journal of Molecular Biology |language=en |volume=327 |issue=5 |pages=1013–1020 |doi=10.1016/S0022-2836(03)00289-4 |issn=0022-2836}}</ref> Since then, over 40 molecules have been reported to inhibit HIV-1 by binding capsid, with five distinct chemotypes described.<ref name=":3" /> The binding pocket for Lenacapavir was first described in 2009, with the small molecule PF-3450074 (PF74) developed by [[Pfizer]].<ref>{{Cite journal |last=Blair |first=Wade S. |last2=Pickford |first2=Chris |last3=Irving |first3=Stephen L. |last4=Brown |first4=David G. |last5=Anderson |first5=Marie |last6=Bazin |first6=Richard |last7=Cao |first7=Joan |last8=Ciaramella |first8=Giuseppe |last9=Isaacson |first9=Jason |last10=Jackson |first10=Lynn |last11=Hunt |first11=Rachael |last12=Kjerrstrom |first12=Anne |last13=Nieman |first13=James A. |last14=Patick |first14=Amy K. |last15=Perros |first15=Manos |date=2010-12-09 |editor-last=Luban |editor-first=Jeremy |title=HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention |url=https://dx.plos.org/10.1371/journal.ppat.1001220 |journal=PLoS Pathogens |language=en |volume=6 |issue=12 |pages=e1001220 |doi=10.1371/journal.ppat.1001220 |issn=1553-7374 |pmc=PMC3000358 |pmid=21170360}}</ref> PF74 was not developed clinically due to its fast metabolic breakdown and poor [[Bioavailability]], but its binding pocket has been well characterized and frequently targeted.<ref name=":3" />


=== GS-CA1 ===
=== GS-CA1 ===
GS-CA1 is an experimental small-molecule capsid inhibitor developed by [[Gilead Sciences]]. CS-CA1 and GS-6207 are analogues, with both molecules showing promising anti-HIV activity.<ref name=":2" />
GS-CA1 is an experimental small-molecule capsid inhibitor developed by [[Gilead Sciences]]. CS-CA1 and GS-6207 are analogues, with both molecules showing promising anti-HIV activity.<ref name=":2" />


GS-CA1 functions by binding directly to the HIV capsid. This bonding disrupts the uncoating process which inhibits both the release of viral RNA and proteins into the cytoplasm, and also inhibits the production of new capsid shells within the cell.<ref>{{cite journal | vauthors = Yant SR, Mulato A, Hansen D, Tse WC, Niedziela-Majka A, Zhang JR, Stepan GJ, Jin D, Wong MH, Perreira JM, Singer E, Papalia GA, Hu EY, Zheng J, Lu B, Schroeder SD, Chou K, Ahmadyar S, Liclican A, Yu H, Novikov N, Paoli E, Gonik D, Ram RR, Hung M, McDougall WM, Brass AL, Sundquist WI, Cihlar T, Link JO | display-authors = 6 | title = A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model | journal = Nature Medicine | volume = 25 | issue = 9 | pages = 1377–1384 | date = September 2019 | pmid = 31501601 | pmc = 7396128 | doi = 10.1038/s41591-019-0560-x }}</ref>
GS-CA1 functions by binding directly to the HIV capsid. This bonding disrupts the uncoating process which inhibits both the release of viral RNA and proteins into the cytoplasm, and also inhibits the production of new capsid shells within the cell.<ref>{{cite journal | vauthors = Yant SR, Mulato A, Hansen D, Tse WC, Niedziela-Majka A, Zhang JR, Stepan GJ, Jin D, Wong MH, Perreira JM, Singer E, Papalia GA, Hu EY, Zheng J, Lu B, Schroeder SD, Chou K, Ahmadyar S, Liclican A, Yu H, Novikov N, Paoli E, Gonik D, Ram RR, Hung M, McDougall WM, Brass AL, Sundquist WI, Cihlar T, Link JO | display-authors = 6 | title = A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model | journal = Nature Medicine | volume = 25 | issue = 9 | pages = 1377–1384 | date = September 2019 | pmid = 31501601 | pmc = 7396128 | doi = 10.1038/s41591-019-0560-x }}</ref>
[[File:Ebselen-2D-skeletal.png|thumb|Structure of ebselen.|left]]
[[File:Ebselen-2D-skeletal.png|thumb|Structure of ebselen.|left]]


=== Ebselen ===
=== Ebselen ===
[[Ebselen]] was identified as a capsid inhibitor using a [[Fluorescence in the life sciences|fluorescence assay]] on a library of pharmacological compounds. Ebselen covalently bonds to the C-terminal domain of the HIV capsid, which inhibits the uncoating process. Ebselen shows anti-HIV activity in infected cell lines.<ref name=":0" />
[[Ebselen]] was identified as a capsid inhibitor using a [[Fluorescence in the life sciences|fluorescence assay]] on a library of pharmacological compounds. Ebselen covalently bonds to the C-terminal domain of the HIV-1 capsid, which inhibits the uncoating process. Ebselen shows anti-HIV activity in infected cell lines.<ref name=":0" />

=== Peptides ===
[[Phage display]] was used to identify [[Peptide|peptides]] that bind the HIV-1 capsid protein, and the most promising peptide inhibitor was the Capsid Assembly Inhibitor (CAI) peptide.<ref name=":4">{{Cite journal |last=Sticht |first=Jana |last2=Humbert |first2=Michael |last3=Findlow |first3=Stuart |last4=Bodem |first4=Jochen |last5=Müller |first5=Barbara |last6=Dietrich |first6=Ursula |last7=Werner |first7=Jörn |last8=Kräusslich |first8=Hans-Georg |date=2005-08 |title=A peptide inhibitor of HIV-1 assembly in vitro |url=https://www.nature.com/articles/nsmb964 |journal=Nature Structural & Molecular Biology |language=en |volume=12 |issue=8 |pages=671–677 |doi=10.1038/nsmb964 |issn=1545-9985}}</ref> CAI prevented the formation of mature capsids, but its poor permeability in cells limited its use.<ref name=":4" /> Other peptide inhibitors have been reported,<ref>{{Cite journal |last=Bocanegra |first=Rebeca |last2=Nevot |first2=María |last3=Doménech |first3=Rosa |last4=López |first4=Inmaculada |last5=Abián |first5=Olga |last6=Rodríguez-Huete |first6=Alicia |last7=Cavasotto |first7=Claudio N. |last8=Velázquez-Campoy |first8=Adrián |last9=Gómez |first9=Javier |last10=Martínez |first10=Miguel Ángel |last11=Neira |first11=José Luis |last12=Mateu |first12=Mauricio G. |date=2011-09-08 |title=Rationally Designed Interfacial Peptides Are Efficient In Vitro Inhibitors of HIV-1 Capsid Assembly with Antiviral Activity |url=https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0023877 |journal=PLOS ONE |language=en |volume=6 |issue=9 |pages=e23877 |doi=10.1371/journal.pone.0023877 |issn=1932-6203 |pmc=PMC3169566 |pmid=21931621}}</ref> as well as next generation inhibitors with increased stability, permeability, and antiviral activity.<ref>{{Cite journal |last=Zhang |first=Hongtao |last2=Zhao |first2=Qian |last3=Bhattacharya |first3=Shibani |last4=Waheed |first4=Abdul A. |last5=Tong |first5=Xiaohe |last6=Hong |first6=Anita |last7=Heck |first7=Susanne |last8=Curreli |first8=Francesca |last9=Goger |first9=Michael |last10=Cowburn |first10=David |last11=Freed |first11=Eric O. |last12=Debnath |first12=Asim K. |date=2008-05-02 |title=A Cell-penetrating Helical Peptide as a Potential HIV-1 Inhibitor |url=https://www.sciencedirect.com/science/article/pii/S0022283608002763 |journal=Journal of Molecular Biology |language=en |volume=378 |issue=3 |pages=565–580 |doi=10.1016/j.jmb.2008.02.066 |issn=0022-2836 |pmc=PMC2695608 |pmid=18374356}}</ref> These peptides interact at the C-terminal domain of the HIV-1 capsid, similar to Ebselen.<ref name=":3" />


== Uracil-based drugs ==
=== Uracil-based drugs ===
Uracil based scaffolds such as bispyrimidine dione and tetrapyrimidine dione derivatives have shown activity as HIV-1 p24 capsid inhibitors in an ''in vitro'' setting but need further exploration.<ref>{{cite journal |last1=Ramesh |first1=Deepthi |last2=Mohanty |first2=Amaresh Kumar |last3=De |first3=Anirban |last4=Vijayakumar |first4=Balaji Gowrivel |last5=Sethumadhavan |first5=Aiswarya |last6=Muthuvel |first6=Suresh Kumar |last7=Mani |first7=Maheswaran |last8=Kannan |first8=Tharanikkarasu |title=Uracil derivatives as HIV-1 capsid protein inhibitors: design, in silico, in vitro and cytotoxicity studies |journal=RSC Advances |date=7 June 2022 |volume=12 |issue=27 |pages=17466–17480 |doi=10.1039/D2RA02450K |pmid=35765450 |pmc=9190787 |bibcode=2022RSCAd..1217466R |url=https://doi.org/10.1039/D2RA02450K |language=en |issn=2046-2069}}</ref>
Uracil based scaffolds such as bispyrimidine dione and tetrapyrimidine dione derivatives have shown activity as HIV-1 p24 capsid inhibitors in an ''in vitro'' setting but need further exploration.<ref>{{cite journal |last1=Ramesh |first1=Deepthi |last2=Mohanty |first2=Amaresh Kumar |last3=De |first3=Anirban |last4=Vijayakumar |first4=Balaji Gowrivel |last5=Sethumadhavan |first5=Aiswarya |last6=Muthuvel |first6=Suresh Kumar |last7=Mani |first7=Maheswaran |last8=Kannan |first8=Tharanikkarasu |title=Uracil derivatives as HIV-1 capsid protein inhibitors: design, in silico, in vitro and cytotoxicity studies |journal=RSC Advances |date=7 June 2022 |volume=12 |issue=27 |pages=17466–17480 |doi=10.1039/D2RA02450K |pmid=35765450 |pmc=9190787 |bibcode=2022RSCAd..1217466R |url=https://doi.org/10.1039/D2RA02450K |language=en |issn=2046-2069}}</ref>


Revision as of 20:15, 25 May 2023

In the management of HIV/AIDS, HIV capsid inhibitors are antiretroviral medicines that target the capsid shell of the virus. Most current antiretroviral drugs used to treat HIV do not directly target the viral capsid.[1] These have also been termed "Capsid-targeting Antivirals", "Capsid Effectors", and "Capsid Assembly Modulators (CAMs)". Because of this, drugs that specifically inhibit the HIV capsid are being developed in order to reduce the replication of HIV, and treat infections that have become resistant to current antiretroviral therapies.[2]

History and background

Structure of HIV capsid obtained from crystallography.

HIV capsid

The mechanism of HIV infection involves the transport and integration of the viral genome into the DNA of the host cell. This process involves both viral and cellular proteins which reverse transcribe the viral RNA to double-stranded DNA, and incorporate the viral DNA into the host cell genome.[3]

The capsid surrounding the viral RNA, nucleocapsids, reverse transcriptase, and integrase plays a key role in the infection process. The capsid is composed of amino- and carboxy-terminal domains that form hexameric and pentameric rings. These rings assemble to form a cone-shaped structure surrounding the viral RNA and proteins.[4] Upon entering the cytoplasm of a host cell, the capsid goes through an unfolding process that releases the viral RNA and proteins into the cell.[citation needed]

The uncoating process is a highly ordered multistep process in which the capsid is weakened and most or all capsid proteins are removed from the shell. Upsetting this process can have downstream effects that significantly reduce the infectivity of the virus. Because of this, capsid uncoating is a favorable target for antiretroviral medicines.[5]

HIV treatment

Current drugs administered in the treatment of HIV do not target the capsid. Instead, patients are given a cocktail of reverse transcriptase inhibitors, protease inhibitors, integrase inhibitors, and entry inhibitors.[6] These drugs have been successful on an epidemiologic and individual basis. With treatment, people infected by HIV are able to live long and healthy lives.[7]

As current treatments significantly reduce the mortality and morbidity of HIV, the disease is incurable but chronically manageable. Because patients typically need to take antiretroviral medications for the rest of their lives, long-term effects of HIV treatment are important to consider. Long term toxicological effects of antiretroviral treatments can sometimes cause secondary morbidities even when the viral count is low.[7] Additionally, drug resistances can be acquired or transmitted due to suboptimal pharmokinetics or lack of patient adherence to treatment.[8]

Therapeutic applications

Structure of Lenacapavir (GS-6207).

Lenacapavir

Lenacapavir is a capsid inhibitor developed by Gilead Sciences. It functions by binding to the hydrophobic pocket formed by two neighboring protein subunits in the capsid shell.[9] This bond stabilizes the capsid structure and inhibits the functional disassembly of the capsid in infected cells.[9]

Structure of GS-CA1.

Lenacapavir was approved for medical use in the European Union in August 2022,[10] in Canada in November 2022,[11][12] and in the United States in December 2022.[13] Lenacapavir is the first capsid inhibitor to be FDA-approved for treating HIV/AIDS.[13]

Research

History

In 2003, the first compound to bind the HIV-1 capsid was in reported and termed "CAP-1".[14] Since then, over 40 molecules have been reported to inhibit HIV-1 by binding capsid, with five distinct chemotypes described.[2] The binding pocket for Lenacapavir was first described in 2009, with the small molecule PF-3450074 (PF74) developed by Pfizer.[15] PF74 was not developed clinically due to its fast metabolic breakdown and poor Bioavailability, but its binding pocket has been well characterized and frequently targeted.[2]

GS-CA1

GS-CA1 is an experimental small-molecule capsid inhibitor developed by Gilead Sciences. CS-CA1 and GS-6207 are analogues, with both molecules showing promising anti-HIV activity.[9]

GS-CA1 functions by binding directly to the HIV capsid. This bonding disrupts the uncoating process which inhibits both the release of viral RNA and proteins into the cytoplasm, and also inhibits the production of new capsid shells within the cell.[16]

Structure of ebselen.

Ebselen

Ebselen was identified as a capsid inhibitor using a fluorescence assay on a library of pharmacological compounds. Ebselen covalently bonds to the C-terminal domain of the HIV-1 capsid, which inhibits the uncoating process. Ebselen shows anti-HIV activity in infected cell lines.[6]

Peptides

Phage display was used to identify peptides that bind the HIV-1 capsid protein, and the most promising peptide inhibitor was the Capsid Assembly Inhibitor (CAI) peptide.[17] CAI prevented the formation of mature capsids, but its poor permeability in cells limited its use.[17] Other peptide inhibitors have been reported,[18] as well as next generation inhibitors with increased stability, permeability, and antiviral activity.[19] These peptides interact at the C-terminal domain of the HIV-1 capsid, similar to Ebselen.[2]

Uracil-based drugs

Uracil based scaffolds such as bispyrimidine dione and tetrapyrimidine dione derivatives have shown activity as HIV-1 p24 capsid inhibitors in an in vitro setting but need further exploration.[20]

See also

References

  1. ^ "FDA-Approved HIV Medicines | NIH". hivinfo.nih.gov. Retrieved 2023-05-25.
  2. ^ a b c d McFadden, William M.; Snyder, Alexa A.; Kirby, Karen A.; Tedbury, Philip R.; Raj, Monika; Wang, Zhengqiang; Sarafianos, Stefan G. (2021-12-22). "Rotten to the core: antivirals targeting the HIV-1 capsid core". Retrovirology. 18 (1): 41. doi:10.1186/s12977-021-00583-z. ISSN 1742-4690. PMC 8693499. PMID 34937567.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
  3. ^ Isel, Catherine; Ehresmann, Chantal; Marquet, Roland (January 2010). "Initiation of HIV Reverse Transcription". Viruses. 2 (1): 213–243. doi:10.3390/v2010213. PMC 3185550. PMID 21994608.
  4. ^ Pornillos, Owen; Ganser-Pornillos, Barbie K.; Yeager, Mark (January 2011). "Atomic-level modelling of the HIV capsid". Nature. 469 (7330): 424–427. Bibcode:2011Natur.469..424P. doi:10.1038/nature09640. ISSN 1476-4687. PMC 3075868. PMID 21248851.
  5. ^ Ambrose Z, Aiken C (April 2014). "HIV-1 uncoating: connection to nuclear entry and regulation by host proteins". Virology. 454–455: 371–379. doi:10.1016/j.virol.2014.02.004. PMC 3988234. PMID 24559861.
  6. ^ a b Thenin-Houssier S, de Vera IM, Pedro-Rosa L, Brady A, Richard A, Konnick B, et al. (April 2016). "Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication". Antimicrobial Agents and Chemotherapy. 60 (4): 2195–2208. doi:10.1128/AAC.02574-15. PMC 4808204. PMID 26810656.
  7. ^ a b Moreno S, López Aldeguer J, Arribas JR, Domingo P, Iribarren JA, Ribera E, et al. (May 2010). "The future of antiretroviral therapy: challenges and needs". The Journal of Antimicrobial Chemotherapy. 65 (5): 827–835. doi:10.1093/jac/dkq061. PMID 20228080.
  8. ^ Taiwo B, Hicks C, Eron J (June 2010). "Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1". The Journal of Antimicrobial Chemotherapy. 65 (6): 1100–1107. doi:10.1093/jac/dkq096. PMID 20348088.
  9. ^ a b c Bester SM, Wei G, Zhao H, Adu-Ampratwum D, Iqbal N, Courouble VV, et al. (October 2020). "Structural and mechanistic bases for a potent HIV-1 capsid inhibitor". Science. 370 (6514): 360–364. Bibcode:2020Sci...370..360B. doi:10.1126/science.abb4808. PMC 7831379. PMID 33060363.
  10. ^ "Sunlenca EPAR". European Medicines Agency (EMA). 22 June 2022. Archived from the original on 26 August 2022. Retrieved 25 August 2022.
  11. ^ "Sunlenca Product information". Health Canada. 25 April 2012. Retrieved 23 December 2022.
  12. ^ "Sunlenca Product information". Health Canada. 25 April 2012. Retrieved 23 December 2022.
  13. ^ a b "FDA Approves New HIV Drug for Adults with Limited Treatment Options" (Press release). U.S. Food and Drug Administration (FDA). 22 December 2022. Retrieved 23 December 2022. Public Domain This article incorporates text from this source, which is in the public domain.
  14. ^ Tang, Chun; Loeliger, Erin; Kinde, Isaac; Kyere, Samson; Mayo, Keith; Barklis, Eric; Sun, Yongnian; Huang, Mingjun; Summers, Michael F (2003-04-11). "Antiviral Inhibition of the HIV-1 Capsid Protein". Journal of Molecular Biology. 327 (5): 1013–1020. doi:10.1016/S0022-2836(03)00289-4. ISSN 0022-2836.
  15. ^ Blair, Wade S.; Pickford, Chris; Irving, Stephen L.; Brown, David G.; Anderson, Marie; Bazin, Richard; Cao, Joan; Ciaramella, Giuseppe; Isaacson, Jason; Jackson, Lynn; Hunt, Rachael; Kjerrstrom, Anne; Nieman, James A.; Patick, Amy K.; Perros, Manos (2010-12-09). Luban, Jeremy (ed.). "HIV Capsid is a Tractable Target for Small Molecule Therapeutic Intervention". PLoS Pathogens. 6 (12): e1001220. doi:10.1371/journal.ppat.1001220. ISSN 1553-7374. PMC 3000358. PMID 21170360.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
  16. ^ Yant SR, Mulato A, Hansen D, Tse WC, Niedziela-Majka A, Zhang JR, et al. (September 2019). "A highly potent long-acting small-molecule HIV-1 capsid inhibitor with efficacy in a humanized mouse model". Nature Medicine. 25 (9): 1377–1384. doi:10.1038/s41591-019-0560-x. PMC 7396128. PMID 31501601.
  17. ^ a b Sticht, Jana; Humbert, Michael; Findlow, Stuart; Bodem, Jochen; Müller, Barbara; Dietrich, Ursula; Werner, Jörn; Kräusslich, Hans-Georg (2005-08). "A peptide inhibitor of HIV-1 assembly in vitro". Nature Structural & Molecular Biology. 12 (8): 671–677. doi:10.1038/nsmb964. ISSN 1545-9985. {{cite journal}}: Check date values in: |date= (help)
  18. ^ Bocanegra, Rebeca; Nevot, María; Doménech, Rosa; López, Inmaculada; Abián, Olga; Rodríguez-Huete, Alicia; Cavasotto, Claudio N.; Velázquez-Campoy, Adrián; Gómez, Javier; Martínez, Miguel Ángel; Neira, José Luis; Mateu, Mauricio G. (2011-09-08). "Rationally Designed Interfacial Peptides Are Efficient In Vitro Inhibitors of HIV-1 Capsid Assembly with Antiviral Activity". PLOS ONE. 6 (9): e23877. doi:10.1371/journal.pone.0023877. ISSN 1932-6203. PMC 3169566. PMID 21931621.{{cite journal}}: CS1 maint: PMC format (link) CS1 maint: unflagged free DOI (link)
  19. ^ Zhang, Hongtao; Zhao, Qian; Bhattacharya, Shibani; Waheed, Abdul A.; Tong, Xiaohe; Hong, Anita; Heck, Susanne; Curreli, Francesca; Goger, Michael; Cowburn, David; Freed, Eric O.; Debnath, Asim K. (2008-05-02). "A Cell-penetrating Helical Peptide as a Potential HIV-1 Inhibitor". Journal of Molecular Biology. 378 (3): 565–580. doi:10.1016/j.jmb.2008.02.066. ISSN 0022-2836. PMC 2695608. PMID 18374356.{{cite journal}}: CS1 maint: PMC format (link)
  20. ^ Ramesh, Deepthi; Mohanty, Amaresh Kumar; De, Anirban; Vijayakumar, Balaji Gowrivel; Sethumadhavan, Aiswarya; Muthuvel, Suresh Kumar; Mani, Maheswaran; Kannan, Tharanikkarasu (7 June 2022). "Uracil derivatives as HIV-1 capsid protein inhibitors: design, in silico, in vitro and cytotoxicity studies". RSC Advances. 12 (27): 17466–17480. Bibcode:2022RSCAd..1217466R. doi:10.1039/D2RA02450K. ISSN 2046-2069. PMC 9190787. PMID 35765450.
Retrieved from "https://en.wikipedia.org/w/index.php?title=HIV_capsid_inhibition&oldid=1157020531"